Saloni Dalwadi

Dr. Saloni Dalwadi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2024 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
HRHardik Bhupendra Rana
Hardik Bhupendra Rana
PPPriyanka Pathak
Priyanka Pathak
VPVimal Patel
Vimal Patel
Vaishali ThakkarVaishali Thakkar
Vaishali Thakkar
MDMansi Dholakia
Mansi Dholakia
TGTejal Gandhi
Tejal Gandhi
Background: The intersubject variability which was related to the genetic makeup was the major cause of change in pharmacological and pharmacokinetic behavior of same dosage form in varied human being. 3D printing technology will help therapy evolve and eliminate the limitations of conventional technologies. Nebivolol's (NBL)-limited oral bioavailability is mainly due to its poor aqueous solubility. The research aims to combine advanced 3D printing technology and nanotechnology to design customized therapy and enhance the functionality of NBL using a statistical approach. Results and discussion: The results of the phase solubility indicated that NBL was a poorly aqueous soluble drug. Its solubility was increased by employing nanoparticle drug delivery, which is a promising solubility enhancement technique. The 32 full factorial design was employed to develop and optimize bionanoparticles (BNPs) by solvent evaporation technique using poly (lactic-co-glycolic acid 50:50) (PLGA 50:50) and poloxamer-407 as a surfactant. The BNPs were characterized by % encapsulation efficiency (% EE), Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimeter (DSC), transmission electron microscope (TEM), zeta potential, polydispersity index (PDI), particle size, in vitro drug release, etc. The BNPs loaded of NBL were further incorporated into the multichannel 3D-controlled release tablets made by PVA filaments employing fused deposition modeling (FDM) technology optimized by central composite design (CCD). Multichannel 3D-printed bionanoparticles-loaded tablet (M3DPBT) was optimized using CCD. All designed M3DPBTs were evaluated for post-fabrication parameters. The optimized M3DPBT could release more than 85% NBL within 10 h. Conclusions: The newly fabricated M3DPBT was found stable. The amount of PLGA 50:50 and Polaxomer was significant for developing BNPs. % infill and layer height were observed as critical for the designing M3DPBT. The combined novel 3D printing and nanotechnology technology will open a new direction for patient compliance and better therapeutic effects. Graphical Designing and developing of M3DPBT is substantially improve the patient compliance and therapeutic effectiveness of Nebivolol.

1 February 2022 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
TGTejal Gandhi
Tejal Gandhi
BPBhagyabhumi Patel
Bhagyabhumi Patel
DPDivya Patel
Divya Patel
SDSaloni Dalwadi
Saloni Dalwadi
VTVaishali Thakkar
Vaishali Thakkar
Background: The use of herbal medicine in inflammatory bowel disease (IBD) has increased significantly. Allopathic treatment of IBD leads to several side effects; therefore, the use of the herbal formulation is promising. Aegle Marmelos, Bombax malabericum, and Hollarrhena antidysentrica plants have been used to treat IBD.Objective: This study aimed to evaluate a designed polyherbal formulation in experimentally induced inflammatory bowel disease in rats and validate a mathematical model derived by Box-Behnken experimental design for optimized polyherbal formulation for the treatment of IBD in experimental rats by checkpoint analysis.Method: Three-level Box-Behnken design was selected to optimize the dose. Polyherbal formulation that consisted of plant extracts of Aegle Marmelos (X1), Bombax malabericum (X2), and Hollarrhena antidysentrica (X3) in different ratios was selected as an independent variable. Polynomial equations were established based on analysis of variance (ANOVA). To validate the chosen polynomial equation, checkpoint analyses were performed. The percentage of predictive error is presented.Results: ANOVA reveals that X2 plant does not have any significant impact on the response surface. The checkpoint batch showed the experimental values of CMDI and Disease activity index (DAI) as 1.33 and 0.66, respectively. It is worthwhile to note that the observed values were quite close to the calculated values of CMDI. A little difference in the value of DAI may be attributed to the inherent variation observed in animal studies.Conclusion: From this study, it was concluded that a dose of 100 mg/kg of Aegle marmelos, a dose of 300 mg/kg of Bombax malabericum, and a dose of 200 mg/kg of Holarrhena antidysentrica will be effective in IBD patients.

1 February 2024 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
PSPurvi Shah
Purvi Shah
KPKesha Patel
Kesha Patel
KPKalpana Patel
Kalpana Patel
Vaishali ThakkarVaishali Thakkar
Vaishali Thakkar
SDSaloni Dalwadi
Saloni Dalwadi
BBBhavesh Bhavsar
Bhavesh Bhavsar
Background: Glaucoma is widely treated using eye drops, but around 95% of the drug is lost by the ocular barrier resulting in low bioavailability. The incorporation of polymeric nanoparticles into mucoadhesive polymer containing in situ gel is generally helpful in the retention of nanoparticles on the eye and improves the efficacy of the formulation Objective: The objective of the present investigation has to develop polymeric brinzolamide (BRZ) nanoparticles laden with timolol maleate (TM) in situ gel formulation. Methods: The optimized BRZ nanoparticles were prepared using PLGA by nanoprecipitation technique utilizing 32 full factorial designs (FFD). Healthy New Zealand White Rabbit (250-300 g) was used for the pharmacokinetic and pharmacodynamic study. Design of the experiment was applied to optimize formulation and validate the model. Some evaluation parameters related to BRZ nanoparticles as well as in-situ gel, have been done Results: The results of FFD reveal that the optimized condition for drugs to polymer ratio (1:7) containing 0.98 %w/v for poloxamer 188 results in higher entrapment efficiency and drug release with 156.7 nm particle size. The in-situ gel formulation has been prepared using Gelrite (0.5%w/v), and HPMC K4M (0.5%w/v) shows acceptable results with sustained drug release up to 6±0.1 h. The rabbit model's in-vivo pharmacokinetics and pharmacodynamic data showed sustained release of drugs longer than the marketed formulation. Conclusion: The proposed formulation could successfully deliver therapeutic concentrations in the eye with prolonged resident time and serve as a potential alternative for the treatment of glaucoma.

1 October 2021 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
SDSaloni Dalwadi
Saloni Dalwadi
Vaishali ThakkarVaishali Thakkar
Vaishali Thakkar
HRHardik Bhupendra Rana
Hardik Bhupendra Rana
Background: A combination of Glimepiride and Boswellia serrata extract reduces neuropathic diabetic complications by reducing the peroxidase level and improving the antioxidant level. The hybrid liquisolid method includes a combination of two methods, kneading and the liquisolid method, to enhance the drug’s in-vitro performance. Objective: The objective of this study was to enhance the in-vitro performance of antidiabetics drugs. Method: Tablets involving a fixed-dose combination of Glimepiride and Boswellia serrata extract were formulated by kneading method followed by liquisolid method. Screening of non-volatile solvents, carriers, and coating materials was carried out. The experiment was designed to optimize the formulation and the obtained model was validated concerning the design of the experiment. 3 level 2 factorial (32) design was applied by using Design expert software 11. Various pre-compression parameters were assessed to check the quality of the formulation. Results: Screening of excipients for kneading method, including Glimepiride with PVP K 30 (5%), and Boswellia serrata extract with Poloxamer 188 (13%), provided optimum drug release. For the liquisolid method, propylene glycol:PEG 400: Tween 80 (1:2:4) ratio for Glimepiride and PEG 400: Tween 80 (1:3) ratio for Boswellia serrata extract were selected. Common carrier and coating material for both drugs were selected to improve the in-vitro performance of the drug. Conclusion: This study enables an overall understanding of the impact of excipients on the quality of formulation, which may provide critical knowledge for the implementation of liquisolid systems.


22 April 2024 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
Vaishali ThakkarVaishali Thakkar
Vaishali Thakkar
SDSaloni Dalwadi
Saloni Dalwadi
ASAkshat Shah
Akshat Shah
PSPurvi Shah
Purvi Shah
DTDevang Tandel
Devang Tandel
Curcumin and Artemisinin are proposed to be formulated as combination therapy to expand the antimalarial effect in resistant and liable isolates. The present research work was to develop and validate a simple, accurate, precise, high-performance thin layer chromatographic method for simultaneous determination of Curcumin and Artemisinin. The chromatographic separation was carried out on a precoated silica gel aluminum plate, 20 × 20 cm, 100μm thickness, with a mixture of Hexane, Toluene and Ethyl acetate (6:1:3) as mobile phase UV detection was performed at 496nm. The Rf were 0.23 and 0.76 for Curcumin and Artemisinin, respectively. Calibration plots were linear over the concentration range 200-1000ng/band for both Curcumin and Artemisinin. The method was validated in accordance with ICH Q2(R1) guidelines for linearity, sensitivity accuracy, precision, and robustness. The percent recoveries in terms of accuracy for the synthetic mixture were found to be 99.8% to 100.0% and 99.94% to 100.4%, and the pooled percent relative standard deviation for repeatability and intermediate precision studies was found to be 0.015-0.042% and 0.008-0.070% for Curcumin and Artemisinin, respectively. A factorial design was used to optimize the chromatographic conditions for the robustness study. In conclusion, a novel, simple, accurate and reproducible HPTLC method was developed and could be applied for quality control testing of Curcumin and Artemisinin in synthetic mixture.